Modified conditioning for blast phase CML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a modified conditioning regimen (a drug treatment given before a stem cell transplant) for people with chronic myeloid leukemia that has entered blast phase, an aggressive stage of the disease. The goal is to help prepare the body for a transplant and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have chronic myeloid leukemia (CML) that has progressed to blast phase, meaning there are many abnormal cells in your blood or bone marrow.
- You must be 18 years or older.
- You need adequate liver, kidney, pancreas, and heart function, as checked by routine tests.
- You must test negative for HIV, hepatitis B, and hepatitis C.
- You need to be physically able to do daily activities (ECOG performance status 0-2).
- You must not have had a stem cell transplant before, and you must not have another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This trial tests a stronger chemotherapy regimen before a stem cell transplant to see if it can reduce the chance of leukemia coming back. It is for adults with acute myeloid leukemia who are in first remission.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.